VYNE Therapeutics Inc. Common Stock
VYNE
Closed
$0.63
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. The company is headquartered in Bridgewater, New Jersey and currently employs 10 full-time employees. The company went IPO on 2018-01-25. The company is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The firm has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.
Key stats
Open
$0.67
Volume
27.15K
Market cap
$21.13M
Prev. close
$0.67
Impl / hst vl
-
Open interest
$0.00
$0.58
Day’s Range
$0.86
$0.55
52W Range
$0.69
Valuation
33
Valuation score
Overvalued
P/E
-
P/S
49.48
P/B
0.91
Current ratio
20.86
Debt / Equity
-1.00
ROE
-69.57%
Gross margin
-
Income growth
-25.88%
FCF growth
8.42
Analysts estimates
Consensus rating
Buy
The average rating from top 4 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$2.04
The top 3 analysts forecasts that 12-month price may increase by 223.81%, with a low of $2.02 and a high of $2.10
$2.02
Low
$2.04
Avg
$2.10
High
Current price
Earnings
Q1 ‘26 revenue
$86.00K
Q1 ‘26 net income
-$3.59M
Revenue
Net income
Previous EPS
-$0.08
Estimate EPS
-$0.18
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply